Bevacizumab-EU

DRUG2 trials

Sponsors

Pfizer

Conditions

Advanced Non-squamous NSCLCNon-Small Cell Lung Cancer

Phase 3

A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLC

CompletedNCT02364999

PfizerNon-Small Cell Lung Cancer

Start: 2015-04-30End: 2017-12-31Updated: 2019-02-07

A BRIDGING STUDY OF PF-06439535 (CN) PLUS PACLITAXEL-CARBOPLATIN VERSUS BEVACIZUMAB PLUS PACLITAXEL-CARBOPLATIN IN NSCLC

TerminatedNCT04325698

PfizerAdvanced Non-squamous NSCLC

Start: 2020-06-11End: 2021-05-10Updated: 2024-10-01

Related Papers

Population pharmacokinetic modeling of PF-06439535 (a bevacizumab biosimilar) and reference bevacizumab (Avastin<sup>®</sup>) in patients with advanced non-squamous non-small cell lung cancer.

2019-11-2610 citations

PF-06439535 (a Bevacizumab Biosimilar) Compared with Reference Bevacizumab (Avastin<sup>®</sup>), Both Plus Paclitaxel and Carboplatin, as First-Line Treatment for Advanced Non-Squamous Non-Small-Cell Lung Cancer: A Randomized, Double-Blind Study.

2019-10-0139 citations

A comparative clinical study of PF-06439535, a candidate bevacizumab biosimilar, and reference bevacizumab, in patients with advanced non-squamous non-small cell lung cancer.

Journal of Clinical Oncology2018-05-203 citations